Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1521 - Geriatric assessment of elderly chemotherapy-naïve patients treated with trabectedin for advanced soft tissue sarcomas (STS): The E-TRAB study of the German Interdisciplinary Sarcoma Group (GISG-13)


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Geriatric Oncology;  Soft Tissue Sarcomas


Bernd Kasper


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


B. Kasper1, P. Reichardt2, M. Schuler3, P. Hohenberger1

Author affiliations

  • 1 Interdisziplinäres Tumorzentrum, Universitätsklinikum Mannheim, 68167 - Mannheim/DE
  • 2 Interdisziplinäre Onkologie, HELIOS Klinikum Berlin-Buch, Berlin-Buch/DE
  • 3 Onkologie, HELIOS Klinikum Emil von Behring, Berlin/DE


Abstract 1521


More than half of soft tissue sarcoma (STS) patients are diagnosed older than 60 years and prognosis for advanced disease is unfavourable with a median overall survival (OS) of ∼12 months remaining substantially unchanged during the last 20 years. Quality of Life (QoL), especially when collected directly from the patients as Patient Reported Outcome (PRO) measures, has gained increasing interest in cancer care; however, existing data among elderly STS patients are scarce. The rationale of the E-TRAB study is to analyze QoL and PRO data in the elderly population (aged ≥ 60 years) with advanced STS, considered to be unsuited to receive anthracycline-based chemotherapy, and treated with trabectedin as a 1st line therapy.

Trial design

The E-TRAB (GISG-13) study is designed as a non-interventional trial (n = 110). Primary endpoints to be evaluated are OS and QoL. It is hypothesized that OS will not be 

Clinical trial identification


Legal entity responsible for the study



This investigator-initiated (IIT) study was sponsored by GWT-TUD GmbH, Dresden, Germany, with support from PharmaMar, S.A., Madrid, Spain.


B. Kasper: Honoraria and research funding by PharmaMar. P. Reichardt, M. Schuler, P. Hohenberger: Honoraria and research funding from PharmaMar.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.